Given the central role of RAS mutation in MPN and the convergence of SETBP1, PTPN11 and JAK2 encoded proteins on MAPK pathway overactivation, patients carrying mutations in these genes could benefit from treatment with MEK inhibitors. This evidence concerns the gene MAP2K7 and myeloproliferative disorder.